Canadian Patents Database

Claims page

---

Patent Document Number: 2099585

(54) English Title: PHARMACEUTICAL COMPOSITIONS

(54) French Title: COMPOSITIONS PHARMACEUTIQUES

---

Claims:

Note: Claims are shown in the official language in which they were submitted.


-8-

Claims

1. An effervescent pharmaceutical composition for oral use comprising a
compound which acts as a 5HT1-like receptor agonist or a physiologically
acceptable
salt or solvate thereof as active ingredient and a pharmaceutically acceptable
carrier
or excipient,
wherein said compound is 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-
methanesulphonamide.

2. A pharmaceutical composition as claimed in claim 1 wherein said compound is
3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide succinate
(1:1) salt.

3. A pharmaceutical composition as claimed in claim 1 or 2 which further
comprises an alkali metal or alkaline earth metal carbonate or bicarbonate as
a base
component and an aliphatic carboxylic acid or salt thereof as an acid
component.

4. A pharmaceutical composition as claimed in 3 which comprises sodium
bicarbonate as a base component.

5. A pharmaceutical composition as claimed in claim 3 or 4 which comprises
monosodium citrate as an acid component.

6. A pharmaceutical composition as claimed in any one of claims 3 to 5 which
contains 25% to 55% (w/w) an acid component.

7. A pharmaceutical composition as claimed in any one of claims 3 to 6 which
contains 25% to 55% (w/w) a base component.

8. A pharmaceutical composition as claimed in any one of claims 1 to 7 which
further comprises one or more flavouring and/or sweetening agents.




-9-

9. A pharmaceutical composition as claimed in any one of claims 1 to 8 which
further comprises 1% to 4% (w/w) binding agent.

10. A pharmaceutical composition as claimed in any one of claims 1 to 9 which
further comprises 2% to 4% (w/w) lubricant.

11. A pharmaceutical composition as claimed in any one of claims 1 to 10 in
the
unit dosage form of tablets.

12. A pharmaceutical composition as claimed in any one of claims 1 to 10 in
the
unit dosage form of a sachet containing a fixed dose of powder or granules.

13. A pharmaceutical composition as claimed in claim 11 or 12 which contains 1
to
200 mg of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide
or a physiologically acceptable salt or solvate thereof, expressed as the
weight of free
base.

14. An effervescent pharmaceutical composition for oral use comprising 1% to
20% (w/w) 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-
methanesulphonamide succinate (1:1) salt, as active ingredient, 25% to 55%
(w/w)
sodium bicarbonate as a base component and 25% to 55% (w/w) monosodium citrate
as an acid component.

15. A pharmaceutical composition as claimed in claim 14 which contains about
100
mg of active ingredient per unit dose (expressed as the weight of free base).

16. A method for the manufacture of a pharmaceutical composition as claimed in
any one of claims 1 to 15 which comprises processing the components of said
composition by blending to form an effervescent pharmaceutical composition.



-10-

17. Use of an effervescent pharmaceutical composition comprising a compound
which acts as a 5HT1-like receptor agonist or a physiologically acceptable
salt or
solvate thereof for causing selective vasoconstrictor activity.

18. Use as claimed in claim 17 wherein the 5HT1-like receptor agonist is 3-[2-
(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide succinate (1:1)
salt.

19. A method for the manufacture of a pharmaceutical composition according to
claim 16 which further comprises granulating said components of said
composition.

20. An effervescent pharmaceutical composition for oral use for migraine
comprising 20 mg to 150 mg of a compound which is 3-[2-(dimethylamino)ethyl]-N-

methyl-1H-indole-5-methanesulphonamide succinate (1:1) salt as the active
ingredient and 25% to 55% (w/w) sodium bicarbonate as a base component and 25%
to 55% (w/w) monosodium citrate as an acid component, which components react
in
the presence of water to generate a gas.

21. A pharmaceutical composition as claimed in claim 20 which contains about
100
mg of active ingredient per unit dose (expressed as the weight of free base).

22. A pharmaceutical composition as claimed in claim 20 which further
comprises
one or more flavouring and/or sweetening agents.

23. A pharmaceutical composition as claimed in claim 20 which further
comprises
1% to 4% (w/w) binding agent.

24. A pharmaceutical composition as claimed in claim 20 which further
comprises
2% to 4% (w/w) lubricant.



-11-

25. A pharmaceutical composition as claimed in claim 20 in the unit dosage
form of
tablets.

26. A pharmaceutical composition as claimed in any one of claims 1 to 13, for
treating conditions associated with cephalic pain.

27. A pharmaceutical composition as claimed in any one of claims 1 to 13, for
treating migraine.

28. A pharmaceutical composition as claimed in any one of claims 1 to 13, for
treating cluster headache.